SCHEMBL5206153

SCHEMBL5206153

COc1cc2c(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(Cl)c3)ccnc2cc1OCCN1CCN(C)CC1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.77
PDGFRA P16234 7/20 0.68
KIT P10721 3/20 0.68
FGFR2 P21802 1/20 0.68
AXL P30530 1/20 0.68
EGFR P00533 3/20 0.59
SRC P12931 2/20 0.59
FLT3 P36888 2/20 0.59
IGF1R P08069 1/20 0.59
FLT1 P17948 5/20 0.59
FLT4 P35916 5/20 0.59
MET P08581 2/20 0.57
RIPK2 O43353 1/20 0.56
STK10 O94804 1/20 0.56
ABL1 P00519 1/20 0.56
LCK P06239 1/20 0.56
LYN P07948 1/20 0.56
RET P07949 1/20 0.56
PDGFRB P09619 1/20 0.56
BCR P11274 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5202104 0.93 KDR (0.75) KDRPDGFRAKITFGFR2AXL
SCHEMBL5201904 0.90 KDR (0.74) KDRPDGFRAKITFGFR2AXL
SCHEMBL5202435 0.88 KDR (0.87) KDRPDGFRAKITFGFR2AXL
SCHEMBL5204265 0.88 KDR (0.73) KDRPDGFRAKITFGFR2AXL
SCHEMBL5207899 0.87 KDR (0.86) KDRPDGFRAKITFGFR2AXL
SCHEMBL5207839 0.87 KDR (0.77) KDRPDGFRAKITFGFR2AXL
SCHEMBL5208159 0.87 KDR (0.62) KDRPDGFRAKITEGFRSRC
SCHEMBL5208170 0.87 KDR (0.84) KDRPDGFRAKITFGFR2AXL
SCHEMBL5208058 0.86 KDR (0.79) KDRFLT1FLT4
SCHEMBL4487003 0.85 KDR (0.57) KDRPDGFRAKITSRCFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1384712-B1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BREWERY (JP) 2007-03-07 EP disclosed
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-02-01 US disclosed
US-7169789-B2 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-01-30 US disclosed
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-10-21 US disclosed
EP-1384712-A1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BEER KABUSHIKI KAISHA (JP) 2004-01-28 EP disclosed
EP-1153920-B1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BREWERY (JP) 2003-10-29 EP disclosed
EP-1153920-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BEER KABUSHIKI KAISHA (JP) 2001-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives CYTH3, NQO2, NRAS KDR 2466/4885PDGFRA 3108/4885KIT 629/4885
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives RABL3, NRAS, CYTH3 KDR 3106/4885PDGFRA 3103/4885KIT 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.